Xofluza

Xofluza, containing baloxavir marboxil, is an antiviral medication that works by inhibiting a critical enzyme called polymerase acidic endonuclease, which influenza viruses need to replicate. By blocking this enzyme, baloxavir marboxil prevents the virus from multiplying, reducing the severity and duration of flu symptoms. This mechanism targets the virus early in its life cycle, limiting its ability to spread within the body.
Xofluza is used in individuals who have developed flu symptoms, including fever, cough, sore throat, body aches, fatigue, and chills. It is most effective when taken soon after symptom onset, as early intervention helps shorten the course of illness and may reduce the risk of complications such as pneumonia. The medication is also considered for preventing influenza in high-risk populations after confirmed exposure to the virus.
The drug is administered orally in a single dose, providing convenience and rapid absorption. It is processed in the liver and eliminated through both feces and urine. Common effects include diarrhea, headache, nausea, and mild stomach discomfort. Less frequent but serious effects may include allergic reactions or liver function changes, which require monitoring.
Xofluza is not a substitute for vaccination but serves as an important tool in managing active influenza infections and limiting virus spread. Individuals are advised to maintain hydration, rest, and follow supportive care measures while using the medication. Awareness of potential interactions with other medicines and health conditions supports safe use. Through its targeted antiviral action, Xofluza helps control influenza symptoms, supports quicker recovery, and reduces the risk of serious complications, particularly in vulnerable populations.